Alpha Centric Advisors LLC Neurocrine Biosciences Inc Transaction History
Alpha Centric Advisors LLC
- $144 Million
- Q1 2024
A detailed history of Alpha Centric Advisors LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Alpha Centric Advisors LLC holds 7,000 shares of NBIX stock, worth $1.02 Million. This represents 0.67% of its overall portfolio holdings.
Number of Shares
7,000Holding current value
$1.02 Million% of portfolio
0.67%Shares
9 transactions
Others Institutions Holding NBIX
# of Institutions
633Shares Held
94.5MCall Options Held
472KPut Options Held
245K-
Black Rock Inc. New York, NY13.8MShares$2 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.93MShares$1.44 Billion0.03% of portfolio
-
State Street Corp Boston, MA3.99MShares$580 Million0.02% of portfolio
-
Jpmorgan Chase & CO New York, NY2.3MShares$333 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.25MShares$327 Million0.49% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $13.9B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...